-
Product Insights
NewInterleukin 8 – Drugs In Development, 2024
The Interleukin 8 pipeline drugs market research report outlays comprehensive information on the Interleukin 8 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Infectious Disease, Immunology, and Dermatology which include indications of Solid Tumor, Renal Cell Carcinoma, Surgical Wound Infections, Coronavirus Disease 2019 (COVID-19), Inflammation, Chronic Inflammation, Burns, and Venous Leg Ulcers (Crural Ulcer). It also...
-
Product Insights
NewCasein Kinase I Isoform Alpha – Drugs In Development, 2024
The Casein Kinase I Isoform Alpha pipeline drugs market research report outlays comprehensive information on the Casein Kinase I Isoform Alpha targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Dermatology, Genetic Disorders, and Undisclosed which include indications of Colorectal Cancer, Myelodysplastic Syndrome, Burns, Familial Adenomatous Polyposis, and Unspecified. It also reviews key players involved in Casein...
-
Product Insights
NewCollagen Alpha 1 – Drugs In Development, 2024
The Collagen Alpha 1 pipeline drugs market research report outlays comprehensive information on the Collagen Alpha 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Dermatology, Genetic Disorders, Respiratory, and Immunology which include indications of Epidermolysis Bullosa, Burns, Familial Adenomatous Polyposis, Cystic Fibrosis, and Graft Versus Host Disease (GVHD). It also reviews key players involved in Collagen...
-
Product Insights
NewAlkaline Phosphatase – Drugs In Development, 2024
The Alkaline Phosphatase pipeline drugs market research report outlays comprehensive information on the Alkaline Phosphatase targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Genetic Disorders, Dermatology, Cardiovascular, and Gastrointestinal which include indications of Hypophosphatasia, Neurofibromatoses Type I (Von Recklinghausen's Disease), Burns, Pseudoxanthoma Elasticum (PXE or Gronblad Strandberg Syndrome), Atherosclerosis, Ischemia Reperfusion Injury, Ulcerative Colitis, and Celiac Disease....
-
Product Insights
NewCasein Kinase 1 – Drugs In Development, 2024
The Casein Kinase 1 pipeline drugs market research report outlays comprehensive information on the Casein Kinase 1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Oncology, Central Nervous System, Dermatology, and Genetic Disorders which include indications of Colorectal Cancer, Solid Tumor, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Burns, and Familial Adenomatous Polyposis. It also reviews key players involved...
-
Product Insights
NewPutative Fidgetin Like Protein 2 – Drugs In Development, 2024
The Putative Fidgetin Like Protein 2 pipeline drugs market research report outlays comprehensive information on the Putative Fidgetin Like Protein 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Dermatology, Ophthalmology, and Cardiovascular which include indications of Spinal Cord Injury, Erectile Dysfunction, Wounds, Burns, Ophthalmology, Keratitis, and Myocardial Infarction. It also reviews key players...
-
Product Insights
NewGlutamate Receptor Ionotropic NMDA 2B – Drugs In Development, 2024
The Glutamate Receptor Ionotropic NMDA 2B pipeline drugs market research report outlays comprehensive information on the Glutamate Receptor Ionotropic NMDA 2B targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Central Nervous System, Cardiovascular, Respiratory, and Dermatology which include indications of Post-Traumatic Stress Disorder (PTSD), Neurodegenerative Diseases, Cardiac Arrest, Orthostatic Hypotension, Idiopathic Pulmonary Fibrosis, Chronic Cough, and Burns....
-
Product Insights
NewVericel Corp Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Vericel Corp Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Vericel Corp (Vericel) develops and markets advanced cell therapies for sports medicine and severe burn care domain. Its major products include MACI (autologous cultured chondrocytes on porcine collagen membrane) for the treatment of cartilage defects; and Epicel cultured epidermal autografts for skin replacement. It also holds an exclusive license for NexoBrid in North America for the treatment of severe thermal...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SAN-711 in Epilepsy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SAN-711 in Epilepsy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SAN-711 in Epilepsy Drug Details: SAN-711 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mecasermin Rinfabate in Hemorrhage
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mecasermin Rinfabate in Hemorrhage report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mecasermin Rinfabate in Hemorrhage Drug Details: Mecasermin rinfabate (Iplex) is a...